Sionna Therapeutics Inc (SION)

Currency in USD
5.42
-0.10(-1.81%)
Real-time Data·
SION is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.345.72
52 wk Range
4.0154.97
Key Statistics
Prev. Close
5.52
Open
5.54
Day's Range
5.34-5.72
52 wk Range
4.01-54.97
Volume
1.19M
Average Vol. (3m)
1.7M
1-Year Change
-77.2115%
Book Value / Share
5.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SION Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.17
Upside
+179.83%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Sionna Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
10 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 15.17
(+179.83% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Freedom Broker
Hold5.00-8.09%-DowngradeAug 11, 2026
Jones Trading
Hold---DowngradeAug 10, 2026
LifeSci Capital
Hold---DowngradeAug 10, 2026
BTIG
Hold---DowngradeAug 10, 2026
Guggenheim
Hold---DowngradeAug 10, 2026

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.66 / -0.52
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SION Income Statement

Compare SION to Peers and Sector

Metrics to compare
SION
Peers
Sector
Relationship
P/E Ratio
−2.5x−2.5x−0.3x
PEG Ratio
−0.060.110.00
Price / Book
0.9x3.5x2.6x
Price / LTM Sales
-23.9x3.1x
Upside (Analyst Target)
−0.4%121.0%47.6%
Fair Value Upside
Unlock2.2%5.6%Unlock

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.91M17.50%49.45M
Other Institutional Investors
57.93M82.50%362.03M
Public Companies & Retail Investors
0.000.00%0.00
Total
65.84M100.00%411.48M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.22.31%10,071,71262,948
RA Capital Healthcare Fund, L.P.15.29%6,905,62543,160

People Also Watch

40.72
SEPN
-0.18%
17.510
ERAS
+2.52%
27.98
CEVA
-0.53%
136.04
SPCX
+1.52%
508.92
AGX
-1.48%

FAQ

What Is the Sionna Therapeutics (SION) Stock Price Today?

The Sionna Therapeutics stock price today is 5.42 USD.

What Stock Exchange Does Sionna Therapeutics Trade On?

Sionna Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Sionna Therapeutics?

The stock symbol for Sionna Therapeutics is "SION."

What Is the Sionna Therapeutics Market Cap?

As of today, Sionna Therapeutics market cap is 249.57M USD.

What Is Sionna Therapeutics's Earnings Per Share (TTM)?

The Sionna Therapeutics EPS (TTM) is -2.17.

When Is the Next Sionna Therapeutics Earnings Date?

Sionna Therapeutics will release its next earnings report on Nov 11, 2026.

From a Technical Analysis Perspective, Is SION a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sionna Therapeutics Stock Split?

Sionna Therapeutics has split 0 times.

How Many Employees Does Sionna Therapeutics Have?

Sionna Therapeutics has 59 employees.

What is the current trading status of Sionna Therapeutics (SION)?

As of Aug 21, 2026, Sionna Therapeutics (SION) is trading at a price of 5.42 USD, with a previous close of 5.52 USD. The stock has fluctuated within a day range of 5.34 USD to 5.72 USD, while its 52-week range spans from 4.01 USD to 54.97 USD.

What Is Sionna Therapeutics (SION) Price Target According to Analysts?

The average 12-month price target for Sionna Therapeutics is 15.17 USD, with a high estimate of 63 USD and a low estimate of 5 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +179.83% Upside potential.

What Is the SION Premarket Price?

SION's last pre-market stock price is 5.54 USD. The pre-market share volume is 57,670.00, and the stock has decreased by 0.02, or 0.36%.

What Is the SION After Hours Price?

SION's last after hours stock price is 5.53 USD, the stock has decreased by 0.01, or 0.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.